View full PAR profile View Profile
May 22 2017
November 22 2016
February 14 2017
It has unveiled plans to raise as much as £12mln, which should transform the business.
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.